Bristol Myers Squibb (CELG-RI) Net Income - Minority (2009 - 2024)
Bristol Myers Squibb (CELG-RI) reported Net Income - Minority of -$58.0 million for Q3 2024, down 7.41% quarter-over-quarter from -$54.0 million in Q2 2024.
Bristol Myers Squibb (CELG-RI) Net Income - Minority (2009 - 2024) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 15 years of Net Income - Minority data on file, last reported at -$58.0 million in Q3 2024.
- Net Income - Minority for Q3 2024 came in at -$58.0 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2024 was -$58.0 million (changed N/A YoY), and the FY2023 annual result was -$55.0 million, changed N/A from the prior year.
- Net Income - Minority slipped to -$58.0 million in Q3 2024 per CELG-RI's latest filing, from -$54.0 million in the prior quarter.
- Over five years, Net Income - Minority peaked at -$54.0 million in Q2 2024 and troughed at -$72.0 million in Q3 2020.
- A 4-year average of -$63.6 million and a median of -$66.0 million in 2020 frame the typical range for Net Income - Minority.
- The sharpest annual moves came in 2020 and 2021: Net Income - Minority soared 40.0% in 2020, then slipped 3.03% in 2021.
- A 4-year view of Net Income - Minority shows it stood at -$60.0 million in 2020, then declined by 18.33% to -$71.0 million in 2021, then increased by 22.54% to -$55.0 million in 2023, then declined by 5.45% to -$58.0 million in 2024.
- Business Quant data shows CELG-RI's Net Income - Minority at -$58.0 million in Q3 2024, -$54.0 million in Q2 2024, and -$55.0 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income - Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -58.00 Mn |
| Jun 30, 2024 | -54.00 Mn |
| Dec 31, 2023 | -55.00 Mn |
| Sep 30, 2021 | -71.00 Mn |
| Jun 30, 2021 | -66.00 Mn |
| Mar 31, 2021 | -68.00 Mn |
| Dec 31, 2020 | -60.00 Mn |
| Sep 30, 2020 | -72.00 Mn |
| Jun 30, 2020 | -66.00 Mn |
| Mar 31, 2020 | -66.00 Mn |
| Dec 31, 2019 | -100.00 Mn |
| Sep 30, 2019 | -106.00 Mn |
| Jun 30, 2019 | -102.00 Mn |
| Mar 31, 2019 | -99.00 Mn |
| Dec 31, 2018 | -96.00 Mn |
| Sep 30, 2018 | -110.00 Mn |
| Jun 30, 2018 | -101.00 Mn |
| Mar 31, 2018 | -113.00 Mn |
| Dec 31, 2017 | -106.00 Mn |
| Sep 30, 2017 | -131.00 Mn |